<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">MSJ</journal-id>
<journal-id journal-id-type="hwp">spmsj</journal-id>
<journal-id journal-id-type="nlm-ta">Mult Scler</journal-id>
<journal-title>Multiple Sclerosis Journal</journal-title>
<issn pub-type="ppub">1352-4585</issn>
<issn pub-type="epub">1477-0970</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage UK: London, England</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/1352458511428081</article-id>
<article-id pub-id-type="publisher-id">10.1177_1352458511428081</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Research Papers</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Anti-HHV-6 IgG titer significantly predicts subsequent relapse risk in multiple sclerosis</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name><surname>Simpson</surname><given-names>Steve</given-names><suffix>Jr</suffix></name>
<xref ref-type="aff" rid="aff1-1352458511428081">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Taylor</surname><given-names>Bruce</given-names></name>
<xref ref-type="aff" rid="aff1-1352458511428081">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Dwyer</surname><given-names>Dominic E</given-names></name>
<xref ref-type="aff" rid="aff2-1352458511428081">2</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Taylor</surname><given-names>Janette</given-names></name>
<xref ref-type="aff" rid="aff2-1352458511428081">2</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Blizzard</surname><given-names>Leigh</given-names></name>
<xref ref-type="aff" rid="aff1-1352458511428081">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Ponsonby</surname><given-names>Anne-Louise</given-names></name>
<xref ref-type="aff" rid="aff3-1352458511428081">3</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Pittas</surname><given-names>Fotini</given-names></name>
<xref ref-type="aff" rid="aff4-1352458511428081">4</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Dwyer</surname><given-names>Terence</given-names></name>
<xref ref-type="aff" rid="aff3-1352458511428081">3</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>van der Mei</surname><given-names>Ingrid</given-names></name>
<xref ref-type="aff" rid="aff1-1352458511428081">1</xref>
</contrib>
</contrib-group>
<aff id="aff1-1352458511428081"><label>1</label>Menzies Research Institute Tasmania, University of Tasmania, Australia.</aff>
<aff id="aff2-1352458511428081"><label>2</label>Westmead Hospital, Australia.</aff>
<aff id="aff3-1352458511428081"><label>3</label>Murdoch Children’s Research Institute, University of Melbourne, Australia.</aff>
<aff id="aff4-1352458511428081"><label>4</label>School of Medicine, University of Tasmania, Australia.</aff>
<author-notes>
<corresp id="corresp1-1352458511428081">Steve Simpson, Jr, Private bag 23, Hobart TAS 7001, Australia. Email: <email>steve.simpson@utas.edu.au</email></corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>6</month>
<year>2012</year>
</pub-date>
<volume>18</volume>
<issue>6</issue>
<fpage>799</fpage>
<lpage>806</lpage>
<history>
<date date-type="received">
<day>21</day>
<month>7</month>
<year>2011</year>
</date>
<date date-type="rev-recd">
<day>14</day>
<month>8</month>
<year>2011</year>
</date>
<date date-type="accepted">
<day>5</day>
<month>10</month>
<year>2011</year>
</date>
</history>
<permissions>
<copyright-statement>© The Author(s) 2012</copyright-statement>
<copyright-year>2012</copyright-year>
<copyright-holder content-type="sage">SAGE Publications</copyright-holder>
</permissions>
<abstract>
<p><bold>Background:</bold> Some of the strongest associations with MS onset are for human herpesviruses, particularly Epstein–Barr virus (EBV) and human herpesvirus 6 (HHV-6). Their role in MS clinical course is less clear, however.</p>
<p><bold>Methods:</bold> Prospective cohort of 198 persons with clinically definite MS, followed 2002–5, and serum samples obtained from all subjects at study entry to measure anti-HHV-6 and anti-EBV (Epstein–Barr nuclear antigen [EBNA] and viral capsid antigen [VCA]) IgG titers. Association with relapse evaluated using survival analysis; association with disability/progression evaluated using linear regression or multilevel mixed-effects linear regression.</p>
<p><bold>Results:</bold> For the 145 persons with relapsing–remitting MS followed beyond one review, anti-HHV-6 IgG titer was positively associated with the hazard of relapse with a dose-dependent trend (<italic>p</italic> = 0.003), not affected by adjustment for anti-EBV IgG titers, neither of which were independently associated with relapse. There was no significant association between anti-human herpesvirus IgG titers and baseline-measured disability scores, or change in disability scores; however, anti-HHV-6 IgG titers were 2.8 times higher among progressive-course females than progressive-course males.</p>
<p><bold>Discussion:</bold> These findings suggest that, in addition to a potential etiological role in MS, HHV-6 infection or the immune response to HHV-6 antigens may have an effect on the risk of MS relapses and possibly on progressive courses of MS. The observed effect was directly related to anti-HHV-6 IgG titers and may indicate that either HHV-6 infection or factors associated with an altered humoral immune response to HHV-6 may have an effect on MS clinical course. Anti-HHV-6 IgG titer may be a useful prognostic factor in relapsing–remitting MS clinical course.</p>
</abstract>
<kwd-group>
<kwd>Epidemiology</kwd>
<kwd>Epstein–Barr virus</kwd>
<kwd>human herpesvirus 6</kwd>
<kwd>multiple sclerosis</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="section1-1352458511428081" sec-type="intro">
<title>Introduction</title>
<p>Prominent amongst the environmental factors thought to affect multiple sclerosis (MS) is infection with human herpesviruses, particularly Epstein–Barr virus (EBV)<sup><xref ref-type="bibr" rid="bibr1-1352458511428081">1</xref>,<xref ref-type="bibr" rid="bibr2-1352458511428081">2</xref></sup> and human herpesvirus 6 (HHV-6),<sup><xref ref-type="bibr" rid="bibr3-1352458511428081">3</xref></sup> through direct<sup><xref ref-type="bibr" rid="bibr4-1352458511428081">4</xref></sup> or indirect<sup><xref ref-type="bibr" rid="bibr5-1352458511428081">5</xref><xref ref-type="bibr" rid="bibr6-1352458511428081"/>–<xref ref-type="bibr" rid="bibr7-1352458511428081">7</xref></sup> mechanisms.</p>
<p>While there is evidence in favor of an etiological role for both herpesviruses, reported associations with disease activity are less consistent. Studies examining a relationship with clinical course have focused primarily on serological and viral load markers of viral reactivation, some demonstrating associations<sup><xref ref-type="bibr" rid="bibr8-1352458511428081">8</xref><xref ref-type="bibr" rid="bibr9-1352458511428081"/><xref ref-type="bibr" rid="bibr10-1352458511428081"/><xref ref-type="bibr" rid="bibr11-1352458511428081"/><xref ref-type="bibr" rid="bibr12-1352458511428081"/><xref ref-type="bibr" rid="bibr13-1352458511428081"/>–<xref ref-type="bibr" rid="bibr14-1352458511428081">14</xref></sup> but others not.<sup><xref ref-type="bibr" rid="bibr9-1352458511428081">9</xref>,<xref ref-type="bibr" rid="bibr11-1352458511428081">11</xref>,<xref ref-type="bibr" rid="bibr14-1352458511428081">14</xref><xref ref-type="bibr" rid="bibr15-1352458511428081"/>–<xref ref-type="bibr" rid="bibr16-1352458511428081">16</xref></sup></p>
<p>Given the evidence linking anti-human herpesvirus IgG levels and the risk of MS,<sup><xref ref-type="bibr" rid="bibr1-1352458511428081">1</xref>,<xref ref-type="bibr" rid="bibr3-1352458511428081">3</xref></sup> we hypothesized that higher levels of anti-human herpesvirus IgG may be due to a more vigorous immune response against these viral antigens, in which case there might also be an association with disease course. This has been examined to some extent previously for EBV, though results are conflicting, while for HHV-6 only two studies were found. For EBV, Farrell and colleagues<sup><xref ref-type="bibr" rid="bibr17-1352458511428081">17</xref></sup> found a significant positive association between anti-EBV-Epstein–Barr nuclear antigen (EBNA) IgG and disease activity on MRI; additionally, persons with relapsing–remitting MS (RRMS) had significantly higher anti-EBV-EBNA IgG but significantly lower anti-EBV-viral capsid antigen (VCA) IgG levels than persons with primary progressive MS (PPMS). Anti-EBV-EBNA IgG titers have been positively associated with central nervous system (CNS) T2 or gadolinium-enhancing lesion number,<sup><xref ref-type="bibr" rid="bibr17-1352458511428081">17</xref></sup> and more new lesions over time,<sup><xref ref-type="bibr" rid="bibr17-1352458511428081">17</xref></sup> while in another study serum anti-EBV-VCA IgG levels were higher in MRI-inactive than MRI-active MS.<sup><xref ref-type="bibr" rid="bibr18-1352458511428081">18</xref></sup> Anti-EBV-EBNA IgG titers have been both positively<sup><xref ref-type="bibr" rid="bibr17-1352458511428081">17</xref></sup> and negatively<sup><xref ref-type="bibr" rid="bibr18-1352458511428081">18</xref></sup> associated with the Expanded Disability Status Scale (EDSS), or found to have no significant correlation,<sup><xref ref-type="bibr" rid="bibr19-1352458511428081">19</xref></sup> while anti-EBV-VCA IgG titers have been found to be positively associated with EDSS.<sup><xref ref-type="bibr" rid="bibr18-1352458511428081">18</xref></sup> For HHV-6, the one study which evaluated its role in clinical course, by Villoslada and colleagues,<sup><xref ref-type="bibr" rid="bibr20-1352458511428081">20</xref></sup> found no significant difference in the levels of anti-HHV-6 IgG between RRMS and progressive cases, in keeping with previous findings by Soldan and colleagues.<sup><xref ref-type="bibr" rid="bibr21-1352458511428081">21</xref></sup></p>
<p>No studies to date have examined the relationship between anti-HHV-6 IgG levels and the subsequent risk of relapse or change in disability. We present our findings from a longitudinal prospective cohort study in southern Tasmania, in which we evaluated the relationship between anti-EBV and anti-HHV-6 IgG titers and clinical outcomes in MS.</p>
</sec>
<sec id="section2-1352458511428081" sec-type="methods">
<title>Methods</title>
<sec id="section3-1352458511428081">
<title>Study design</title>
<p>As described elsewhere,<sup><xref ref-type="bibr" rid="bibr22-1352458511428081">22</xref></sup> the Southern Tasmanian Multiple Sclerosis Longitudinal (MSL) Study followed over 2002–5 a cohort of 203 persons with clinically definite MS (2001 McDonald criteria) living in southern Tasmania, Australia. An estimated 78% (203/259) of eligible cases in the region were included, and data from 198 participants were obtained for analysis. When participants discontinued participation or were lost to follow-up, they were censored as of the date of study exit or their last attended review.</p>
<p>The study methodology has been previously described.<sup><xref ref-type="bibr" rid="bibr22-1352458511428081">22</xref></sup> Briefly, at each biannual review participants were asked about their lifestyle, including physical activity, smoking, alcohol and marijuana use, sleep quality/quantity, immunizations in the preceding 6 months, vitamin D supplement use and dosage, and immunomodulatory medication use. Clinical disability, including EDSS and the Multiple Sclerosis Severity Score (MSSS), was measured each winter by a single physician.</p>
<p>Ethics approval was obtained from the Southern Tasmania Human Research Ethics Committee; all participants provided informed consent.</p>
</sec>
<sec id="section4-1352458511428081">
<title>Measurement of relapses</title>
<p>The measurement of relapse has been described in more detail elsewhere.<sup><xref ref-type="bibr" rid="bibr23-1352458511428081">23</xref></sup> Briefly, relapses were reported in real time by phone to the study clinician or subsequently at biannual review, and all relapse reports were validated by the study physician and neurologist.</p>
</sec>
<sec id="section5-1352458511428081">
<title>Biological samples</title>
<p>Serum samples were collected at study entry and at each biannual review and stored at −80°C until use.</p>
<p>Anti-HHV-6, anti-EBV-EBNA, and anti-EBV-VCA IgG titers were measured from samples collected at study entry. Serum anti-HHV-6 IgG titers were measured in parallel using an indirect immunofluorescence assay (IFA) (Panbio Inc., Columbia, MD, USA) according to the manufacturer’s instructions. Dilution series were performed to obtain titers, by a single operator, at the same time in batches, and using positive and negative controls. Serum anti-EBV (VCA and EBNA) IgG titers were measured using an analogous assay (Sigma-Aldrich, Castle Hill, NSW, Australia).</p>
<p>One subject’s results for anti-EBV-EBNA IgG were indeterminate, and thus analysis of this is restricted to 197 persons.</p>
<p>Serum 25-hydroxyvitamin D (25(OH)D) levels were measured as previously described,<sup><xref ref-type="bibr" rid="bibr23-1352458511428081">23</xref></sup> using a commercially available radioimmunoassay (Stillwater, Minnesota-DiaSorin Inc.).</p>
<p>All biological measurements were done after the completion of the study, and thus study investigators were blinded to these covariates when outcome data, including relapse occurrence and measures of disability, were recorded.</p>
</sec>
<sec id="section6-1352458511428081">
<title>Statistical analysis</title>
<p>The distribution of anti-human herpesvirus IgG titers was left skewed. Therefore, when anti-human herpesvirus IgG titer was the dependent variable, the log base 4 transformation was used, such that each increase in titer increases the magnitude by 1.0.</p>
<p>The lowest stratum of each anti-human herpesvirus IgG titer had insufficient numbers to be a reference category for categorical regression analyses. Consequently, the next highest stratum was used for anti-HHV-6 IgG (40) and anti-EBV-VCA IgG (640) titers, and the next highest stratum was used for anti-EBV-EBNA IgG (40) titers.</p>
<p>Analysis of the factors associated with anti-HHV-6 and anti-EBV IgG titers at baseline was done using linear regression.</p>
</sec>
<sec id="section7-1352458511428081">
<title>Survival analysis</title>
<p>The effect of anti-human herpesvirus IgG titers and other covariates on time-to-relapse was calculated using Cox proportional hazards models for repeated events, as described previously,<sup><xref ref-type="bibr" rid="bibr23-1352458511428081">23</xref></sup> whereby multiple relapses by the same persons are treated as independent observations but accounted for at the intra-individual level, and the time until a prior event does not influence the composition of the risk set for a subsequent event.</p>
<p>All covariates satisfied the proportional hazards assumption with the exception of the binary variable for sex and the categorical variable for baseline EDSS (0–&lt;3, 3–&lt;5.5, 5.5–&lt;7.5, 7.5–9). For this reason, all models are stratified to allow the baseline hazards to differ by sex and baseline EDSS category.</p>
<p>Survival proportions are depicted using Kaplan– Meier survival curves showing time to relapse; multiple relapses by the same persons are treated as independent observations.</p>
</sec>
<sec id="section8-1352458511428081">
<title>Disability and progression analyses</title>
<p>Factors associated with baseline-measured disability were assessed by linear regression. Predictors of mean annual change in disability were assessed by multilevel mixed-effects linear regression to account for intra-individual course over time. All analyses were adjusted for age, sex and a dichotomous term (0/1) indicating whether a person was having a relapse at the time of disability score measurement; predictors of mean annual change in EDSS were also adjusted for a categorical term for baseline EDSS as above. Transformation was applied as required to satisfy homoscedasticity; however, all coefficients are reported on the scale of the original disability measure.</p>
<p>For survival analysis and analyses of predictors of disability and progression, subgroup analyses were performed using stratification, and the significance of differences between groups, as well as the significance of multiplicative interaction between covariates, was evaluated by product terms between the corresponding variables.</p>
<p>For all instances of missing data, analyses were restricted to persons with complete data.</p>
<p>All analyses were performed using STATA/SE for Windows (Version 10.1; StataCorp LP College Station, TX, USA).</p>
</sec>
</sec>
<sec id="section9-1352458511428081" sec-type="results">
<title>Results</title>
<sec id="section10-1352458511428081">
<title>Participant characteristics</title>
<p>The cohort of 198 persons was followed for an average of 2.2 (SD 0.5) years. Of those with RRMS at study entry followed beyond one review (145), a total of 122 confirmed relapses occurred in 70 participants (mean: 0.37 relapses per person/year). Follow-up time did not differ by relevant exposure and outcome variables (data not shown). <xref ref-type="table" rid="table1-1352458511428081">Table 1</xref> shows the characteristics of the total cohort and those with RRMS at study entry.</p>
<table-wrap id="table1-1352458511428081" position="float">
<label>Table 1.</label>
<caption><p>Demographic and clinical characteristics of the total cohort and those with relapsing–remitting MS at study entry.</p></caption>
<graphic alternate-form-of="table1-1352458511428081" xlink:href="10.1177_1352458511428081-table1.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="char" char="."/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th/>
<th align="left">Total cohort</th>
<th align="left">RRMS sample</th>
</tr>
<tr>
<th/>
<th align="left"><italic>n</italic> (%)</th>
<th align="left"><italic>n</italic> (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td><bold>Total</bold></td>
<td>198</td>
<td>145</td>
</tr>
<tr>
<td><bold>Female</bold></td>
<td>137 (69.2)</td>
<td>109 (75.2)</td>
</tr>
<tr>
<td><bold>Age at study entry (years)</bold></td>
<td/>
<td/>
</tr>
<tr>
<td>21–38</td>
<td>37 (18.7)</td>
<td>34 (23.5)</td>
</tr>
<tr>
<td>39–44</td>
<td>40 (20.2)</td>
<td>36 (24.8)</td>
</tr>
<tr>
<td>45–51</td>
<td>45 (22.7)</td>
<td>34 (23.5)</td>
</tr>
<tr>
<td>52–77</td>
<td>76 (38.3)</td>
<td>41 (28.3)</td>
</tr>
<tr>
<td><bold>MS course at study entry</bold></td>
<td/>
<td/>
</tr>
<tr>
<td>RRMS</td>
<td>149 (75.3)</td>
<td>145 (100)<sup><xref ref-type="table-fn" rid="table-fn1-1352458511428081">a</xref></sup></td>
</tr>
<tr>
<td>SPMS</td>
<td>40 (20.2)</td>
<td>0</td>
</tr>
<tr>
<td>PPMS</td>
<td>9 (4.6)</td>
<td>0</td>
</tr>
<tr>
<td><bold>Progression to SPMS during study</bold></td>
<td>17 (11.4)</td>
<td>17 (11.7)</td>
</tr>
<tr>
<td><bold>Relapse during study</bold></td>
<td>70 (35.4)</td>
<td>70 (48.3)</td>
</tr>
<tr>
<td><bold>Any immunomodulatory therapy during study?</bold></td>
<td>130 (65.7)</td>
<td>119 (82.1)</td>
</tr>
<tr>
<td><bold>Smoker during study?</bold></td>
<td>49 (24.8)</td>
<td>39 (26.9)</td>
</tr>
<tr>
<td><bold>anti-HHV-6 IgGtiter</bold></td>
<td/>
<td/>
</tr>
<tr>
<td>10</td>
<td>11 (5.6)</td>
<td>9 (6.2)</td>
</tr>
<tr>
<td>40</td>
<td>58 (29.3)</td>
<td>39 (26.9)</td>
</tr>
<tr>
<td>160</td>
<td>90 (45.5)</td>
<td>69 (47.6)</td>
</tr>
<tr>
<td>640</td>
<td>39 (19.7)</td>
<td>28 (19.3)</td>
</tr>
<tr>
<td><bold>anti-EBV-EBNA IgGtiter<sup><xref ref-type="table-fn" rid="table-fn1-1352458511428081">b</xref></sup></bold></td>
<td/>
<td/>
</tr>
<tr>
<td>&lt;10</td>
<td>5 (2.5)</td>
<td>4 (2.8)</td>
</tr>
<tr>
<td>10</td>
<td>10 (5.1)</td>
<td>8 (5.5)</td>
</tr>
<tr>
<td>40</td>
<td>32 (16.2)</td>
<td>23 (15.9)</td>
</tr>
<tr>
<td>160</td>
<td>115 (58.4)</td>
<td>82 (56.6)</td>
</tr>
<tr>
<td>640</td>
<td>35 (17.8)</td>
<td>28 (19.3)</td>
</tr>
<tr>
<td><bold>anti-EBV-VCA IgGtiter</bold></td>
<td/>
<td/>
</tr>
<tr>
<td>160</td>
<td>20 (10.1)</td>
<td>13 (9.0)</td>
</tr>
<tr>
<td>640</td>
<td>119 (60.0)</td>
<td>90 (62.1)</td>
</tr>
<tr>
<td>2560</td>
<td>59 (29.8)</td>
<td>42 (28.9)</td>
</tr>
<tr>
<td/>
<td colspan="2">Mean (SD; Range)</td>
</tr>
<tr>
<td><bold>Age at study entry, years</bold></td>
<td>48.2 (11.4; 21–77)</td>
<td>45.5 (10.4; 21–76)</td>
</tr>
<tr>
<td><bold>MS duration from diagnosis, years</bold></td>
<td>9.2 (8.8; 0–43)</td>
<td>6.9 (7.3; 0–43)</td>
</tr>
<tr>
<td><bold>MS duration from first symptoms, years</bold></td>
<td>14.0 (10.3; 0–58)</td>
<td>11.3 (9.2; 0–58)</td>
</tr>
<tr>
<td><bold>EDSS at study entry</bold></td>
<td>3.7 (2.3; 0–9)</td>
<td>2.8 (1.6; 0–8.5)</td>
</tr>
<tr>
<td><bold>EDSS at study exit</bold></td>
<td>4.3 (2.2; 0–9.5)</td>
<td>3.5 (1.7; 0–8.5)</td>
</tr>
<tr>
<td><bold>MSSS at study entry</bold></td>
<td>4.5 (2.7; 0.1–9.9)</td>
<td>3.8 (2.4; 0.1–9.9)</td>
</tr>
<tr>
<td><bold>MSSS at study exit</bold></td>
<td>5.0 (2.6; 0.1–9.9)</td>
<td>4.3 (2.4; 0.1–9.9)</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn1-1352458511428081">
<label>a</label>
<p>Only 145 of the 149 persons with RRMS at study entry were included in the relapse analysis, since the other four persons only completed one review, precluding survival analysis of the occurrence of relapse. <sup>b</sup>One person did not have a value for anti-EBV-EBNA IgG.</p></fn>
<fn id="table-fn2-1352458511428081">
<p>EBNA: Epstein–Barr nuclear antigen, EBV: Epstein–Barr virus, EDSS: Expanded Disability Status Scale, HHV-6: human herpesvirus 6, MS: multiple sclerosis, MSFC: Multiple Sclerosis Functional Composite, MSSS: Multiple Sclerosis Severity Score, RRMS: relapsing–remitting multiple sclerosis, Scripps: Scripps Neurological Rating Scale, SD: standard deviation, VCA: viral capsid antigen</p></fn>
</table-wrap-foot>
</table-wrap>
</sec>
<sec id="section11-1352458511428081">
<title>Determinants of anti-HHV-6 and anti-EBV IgG titers</title>
<p>Anti-HHV-6 IgG showed no correlation with either anti-EBV-EBNA IgG (<italic>r</italic> = 0.09, <italic>p</italic> = 0.23) or anti-EBV-VCA IgG (<italic>r</italic> = 0.05, <italic>p</italic> = 0.53); similarly, on restriction to persons of RRMS course followed beyond baseline there were no correlations (HHV6-EBNA: <italic>r</italic> = 0.08, <italic>p</italic> = 0.34; HHV6-VCA: <italic>r</italic> = 0.04, <italic>p</italic> = 0.68).</p>
<p>Anti-HHV-6 IgG titers were 1.5 times higher among females than males (<italic>p</italic> = 0.020). On restriction to persons of RRMS course at study entry, this effect was not evident (<italic>p</italic> = 0.51). Neither anti-EBV-VCA nor anti-EBV-EBNA IgG titers differed by sex. The reduction in magnitude of the effect of sex on anti-HHV-6 IgG titer on restriction to RRMS occurred because females with secondary progressive MS (SPMS) and PPMS had significantly higher titers than males (2.8 times higher, <italic>p</italic> = 0.001), persisting on adjustment (<italic>p</italic> = 0.005). Among females, anti-HHV-6 IgG titers were 2.0 times higher for progressive course than for RRMS, though this did not reach statistical significance (<italic>p</italic> = 0.14). Among females with RRMS at baseline, there was no significant difference in anti-HHV-6 IgG titer between females who progressed to SPMS during the study and those who did not (<italic>p</italic> = 0.84). Interestingly, males trended in the opposite direction from females, with anti-HHV-6 IgG titers 1.6 times higher in RRMS than in progressive-course cases (<italic>p</italic> = 0.12), though this was attenuated on adjustment (<italic>p</italic> = 0.20); like females, males showed no association with progression to SPMS after adjustment (<italic>p</italic> = 0.44).</p>
<p>Among persons of RRMS course at study entry, those reporting a relapse during the study had 1.7 times higher titers of anti-HHV-6 IgG than those who did not have relapses (<italic>p</italic> = 0.004). This association remained after adjustment for age, sex, MS course at study exit, serum 25(OH)D and season at time of anti-human herpesvirus IgG measurement, baseline disability, MS duration from diagnosis, and use of immunomodulatory medication during the study (<italic>p</italic> = 0.015).</p>
<p>Other covariates examined in Supplemental <xref ref-type="table" rid="table1-1352458511428081">Tables 1</xref> and <xref ref-type="table" rid="table2-1352458511428081">2</xref>, including age, BMI, duration of disease, 25(OH)D at time of anti-human herpesvirus IgG measurement, smoking behavior and use of immunomodulatory therapy during the review, showed no association with any of the anti-EBV IgG titers, either overall or on restriction to RRMS participants.</p>
<table-wrap id="table2-1352458511428081" position="float">
<label>Table 2.</label>
<caption><p>Association between baseline anti-HHV-6 IgG titers and the hazard of relapse for the full duration (Panel A), and restricted to first year and first 6 months after measure of anti-HHV-6 IgG titers (Panel B). All models adjusted for age and stratified by sex and baseline EDSS category</p></caption>
<graphic alternate-form-of="table2-1352458511428081" xlink:href="10.1177_1352458511428081-table2.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th align="left" rowspan="2" valign="top">A</th>
<th align="left" colspan="4">Full study interval <italic>n</italic> = 122</th>
</tr>
<tr>
<th align="left">Crude HR (95% CI)</th>
<th align="left">Adjusted<sup><xref ref-type="table-fn" rid="table-fn3-1352458511428081">a</xref></sup> HR (95% CI)</th>
<th/>
<th align="left">Adjusted for confounders<sup><xref ref-type="table-fn" rid="table-fn4-1352458511428081">b</xref></sup> HR (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td colspan="5">HHV-6 IgGtiter</td>
</tr>
<tr>
<td>10</td>
<td>1.00 (Reference)</td>
<td>1.00 (Reference)</td>
<td/>
<td>1.00 (Reference)</td>
</tr>
<tr>
<td>40</td>
<td>1.17 (0.29, 4.80)</td>
<td>1.18 (0.29, 4.75)</td>
<td/>
<td>1.09 (0.27, 4.45)</td>
</tr>
<tr>
<td>160</td>
<td>1.82 (0.48, 6.94)</td>
<td>1.88 (0.50, 7.04)</td>
<td/>
<td>1.49 (0.40, 5.59)</td>
</tr>
<tr>
<td>640</td>
<td>2.99 (0.77, 11.66)</td>
<td>3.10 (0.81, 11.91)</td>
<td/>
<td>2.63 (0.66, 10.55)</td>
</tr>
<tr>
<td>Trend</td>
<td><bold><italic>p</italic> = 0.001</bold></td>
<td><bold><italic>p</italic> = 0.001</bold></td>
<td/>
<td><bold><italic>p</italic> = 0.003</bold></td>
</tr>
<tr>
<th align="left" rowspan="2" valign="top"><bold>B</bold></th>
<th align="left" colspan="2">First year restricted (<italic>n</italic> = 52)</th>
<th align="left" colspan="2">First 6 months restricted (<italic>n</italic> = 25)</th>
</tr>
<tr>
<th align="left">Crude HR (95% CI)</th>
<th align="left">Adjusted<sup><xref ref-type="table-fn" rid="table-fn3-1352458511428081">a</xref></sup> HR (95% CI)</th>
<th align="left">Crude HR (95% CI)</th>
<th align="left">Adjusted<sup><xref ref-type="table-fn" rid="table-fn3-1352458511428081">a</xref></sup> HR (95% CI)</th>
</tr>
<tr>
<td colspan="5">HHV-6 IgGtiter</td>
</tr>
<tr>
<td>10</td>
<td>1.00 (Reference)</td>
<td>1.00 (Reference)</td>
<td>1.00 (Reference)</td>
<td>1.00 (Reference)</td>
</tr>
<tr>
<td>40</td>
<td>0.61 (0.17, 2.17)</td>
<td>0.62 (0.18, 2.17)</td>
<td>0.13 (0.02, 1.10)</td>
<td>0.13 (0.02, 1.07)</td>
</tr>
<tr>
<td>160</td>
<td>1.35 (0.45, 4.07)</td>
<td>1.43 (0.48, 4.21)</td>
<td>0.61 (0.22, 1.65)</td>
<td>0.65 (0.23, 1.81)</td>
</tr>
<tr>
<td>640</td>
<td>2.25 (0.69, 7.29)</td>
<td>2.40 (0.77, 7.52)</td>
<td>1.56 (0.57, 4.25)</td>
<td>1.66 (0.63, 4.36)</td>
</tr>
<tr>
<td>Trend</td>
<td><bold><italic>p</italic> = 0.010</bold></td>
<td><bold><italic>p</italic> = 0.008</bold></td>
<td><bold><italic>p</italic> = 0.002</bold></td>
<td><bold><italic>p</italic> = 0.002</bold></td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn3-1352458511428081">
<label>a</label>
<p>Further adjusted for anti-EBV-EBNA and anti-EBV-VCA IgG. <sup>b</sup>Further adjusted for exit course, duration of disease from diagnosis, season at time of anti-human herpesvirus measure, 25(OH)D at time of anti-human herpesvirus measure, body mass index, and use of immunomodulatory therapy during the study.</p></fn>
<fn id="table-fn4-1352458511428081">
<p>CI: confidence interval, EBNA: Epstein–Barr nuclear antigen, EDSS: Expanded Disability Status Scale, HHV: human herpesvirus, HR: hazard ratio, VCA: viral capsid antigen</p></fn>
<fn id="table-fn5-1352458511428081">
<p><italic>n</italic>=the number of relapses included in each analysis.</p></fn>
</table-wrap-foot>
</table-wrap>
</sec>
<sec id="section12-1352458511428081">
<title>Anti-HHV-6 and anti-EBV IgG titers and relapse</title>
<p>We found a strong, dose-dependent association between baseline-measured anti-HHV-6 IgG and the risk of subsequent relapse. This association was not affected by adjustment for anti-EBV-EBNA and anti-EBV-VCA IgG (<xref ref-type="table" rid="table2-1352458511428081">Table 2</xref>, panel A) or by adjustment for potential confounders, including exit course, duration of disease from diagnosis, season at time of anti-human herpesvirus measurement, 25(OH)D at time of anti-human herpesvirus measurement, BMI, and use of immunomodulatory therapy during the study. The association did not differ by sex (<italic>p</italic> = 0.92).</p>
<p><xref ref-type="fig" rid="fig1-1352458511428081">Figure 1</xref> shows that the higher relapse rate among those with higher baseline anti-HHV-6 IgG remains over the full duration of the study. However, as the baseline-measured IgG may be more closely related to earlier than to later occurring relapses, we evaluated the association restricted to the first year and the first 6 months after measurement. As in <xref ref-type="table" rid="table2-1352458511428081">Table 2</xref> (panel B), the association persists in magnitude and significance, despite the reduced numbers of relapses included (122 overall, 52 in the first year, 25 in the first 6 months). No association was found with either of the anti-EBV IgGs in either the 1-year or the 6-month-restricted analyses (data not shown).</p>
<fig id="fig1-1352458511428081" position="float">
<label>Figure 1.</label>
<caption><p>Kaplan–Meier survival plots by category of anti-HHV-6 IgG titer (labeled at end of each line). The plots show the proportion of subjects relapse-free each day since study entry. Multiple relapses by the same persons are treated as independent observations.</p></caption>
<graphic xlink:href="10.1177_1352458511428081-fig1.tif"/>
</fig>
</sec>
<sec id="section13-1352458511428081">
<title>The prospective association between anti-HHV-6 and anti-EBV IgG and clinical disability progression</title>
<p>We estimated the association between anti-human herpesvirus IgG and baseline-measured disability, with a positive change indicating a higher level of disability. There was no association between anti-HHV-6 IgG, anti-EBV-EBNA IgG or anti-EBV-VCA and either baseline-measured EDSS or MSSS. We next estimated the annual change in disability at each antibody level, with a positive change indicating a worsening in disability. There was no evidence that higher anti-human herpesvirus IgG level was associated with higher or lower change in EDSS or MSSS (Supplemental Table 3). No significant differences were found by sex or by MS type (data not shown).</p>
</sec>
</sec>
<sec id="section14-1352458511428081" sec-type="discussion">
<title>Discussion</title>
<p>Using one of the largest and longest-follow-up prospective cohorts evaluating the role of anti-HHV-6 and anti-EBV IgG in the clinical course of MS, we have demonstrated a dose-dependent positive association between baseline-measured serum anti-HHV-6 IgG titers and the subsequent hazard of relapse, persisting on adjustment for anti-EBV IgG. While no anti-HHV-6 or EBV IgG titers were significantly associated with disability, anti-HHV-6 IgG titer was differentially associated by sex with MS course.</p>
<sec id="section15-1352458511428081">
<title>Anti-HHV-6 and anti-EBV IgG and relapse</title>
<p>The discovery of a strong, dose-dependent relationship between baseline anti-HHV-6 IgG and the subsequent hazard of relapse is an interesting and novel finding. While a possible initial interpretation is that higher titers reflect nonspecific immune response against herpesvirus, the absence of similar trends for EBV argues against this, suggesting a specific anti-HHV-6 response. It seems that the immune response is specific solely to HHV-6 antigens, or host antigens resembling HHV-6, and may denote increased risk via molecular mimicry and similarity of HHV-6-specific antigens with host antigens in the CNS.<sup><xref ref-type="bibr" rid="bibr7-1352458511428081">7</xref></sup> A further possibility is that the immune response against HHV-6 is proportionate to the level, either current or recent, of HHV-6 and that the virus is manifesting in greater disease activity through overt cytolytic replication and resultant inflammation. HHV-6 has been found in the CNS of patients with MS<sup><xref ref-type="bibr" rid="bibr24-1352458511428081">24</xref></sup> and MS-associated lesions,<sup><xref ref-type="bibr" rid="bibr25-1352458511428081">25</xref></sup> so certainly this is possible. HHV-6 has a number of potentially etiologic effects, including latency in<sup><xref ref-type="bibr" rid="bibr26-1352458511428081">26</xref>,<xref ref-type="bibr" rid="bibr27-1352458511428081">27</xref></sup> and induction of neurotoxic behavior in some glial cells.<sup><xref ref-type="bibr" rid="bibr28-1352458511428081">28</xref></sup> HHV-6 uses the surface protein CD46 to enter cells, which has been demonstrated to induce production of interleukin-1β and interleukin-17,<sup><xref ref-type="bibr" rid="bibr29-1352458511428081">29</xref></sup> and HHV-6 encodes a viral version of the CCR2 ligand, which acts as a chemo-attractant for monocytes and macrophages.<sup><xref ref-type="bibr" rid="bibr30-1352458511428081">30</xref></sup> Also, HHV-6 has the capacity to transactivate other latent herpesviruses and human endogenous retroviruses (HERV),<sup><xref ref-type="bibr" rid="bibr31-1352458511428081">31</xref>,<xref ref-type="bibr" rid="bibr32-1352458511428081">32</xref></sup> translated components of which have been found to be pro-inflammatory,<sup><xref ref-type="bibr" rid="bibr33-1352458511428081">33</xref></sup> neurotoxic and gliotoxic.<sup><xref ref-type="bibr" rid="bibr34-1352458511428081">34</xref></sup></p>
</sec>
<sec id="section16-1352458511428081">
<title>Anti-HHV-6 and anti-EBV IgGs, sex and MS course</title>
<p>Anti-HHV-6 IgG titers were similar in females and males within the RRMS group, but, among those with progressive courses of MS, titers were 2.8 times higher in females than in males. Viewed differently, progressive females had titers 2.0 times higher than RRMS females, while progressive males had titers 1.6 times lower than RRMS males, although this was not statistically significant. Anti-HHV-6 IgG titer did not differ between those who progressed to SPMS during the study and those who did not, overall or by sex.</p>
<p>We found no difference in titers of anti-EBV-EBNA or anti-EBV-VCA IgG by sex or by MS course. These findings are at odds with the results of other studies using similar methodologies.<sup><xref ref-type="bibr" rid="bibr17-1352458511428081">17</xref>,<xref ref-type="bibr" rid="bibr20-1352458511428081">20</xref>,<xref ref-type="bibr" rid="bibr21-1352458511428081">21</xref>,<xref ref-type="bibr" rid="bibr35-1352458511428081">35</xref></sup> Villoslada and colleagues<sup><xref ref-type="bibr" rid="bibr20-1352458511428081">20</xref></sup> found significantly lower anti-HHV-6 IgM detection frequencies in SPMS than in MSMS, as well as lower anti-HHV-6 IgM titers in SPMS than in RRMS. Despite the mainly female cohort, these trends are analogous to our findings among males, and may reflect population-specific effects.</p>
</sec>
<sec id="section17-1352458511428081">
<title>Anti-HHV-6 and anti-EBV IgG and disability</title>
<p>We found no significant association between anti-human herpesvirus IgGs and baseline-measured EDSS or MSSS, or with mean annual change over time. Castallazzi and colleagues recently reported a positive association between EDSS and anti-EBV VCA IgG and a negative association with anti-EBV EBNA IgG, but found little evidence of anti-EBV intrathecal immune activity and concluded that immune response to EBV is unlikely to be the mediator of MS immunopathology.<sup><xref ref-type="bibr" rid="bibr18-1352458511428081">18</xref></sup> The observed positive association with VCA-specific IgG and increased disability, but not with EBNA-specific IgG, could reflect activity of EBV replicative proteins but not viral assembly, or might reflect that EBV is not the direct causative agent, but rather is transactivating something else, possibly HHV-6 and/or HERV.</p>
</sec>
<sec id="section18-1352458511428081">
<title>Strengths and weaknesses</title>
<p>This study is stronger than previous studies by virtue of its prospective design, longer follow-up time and larger cohort size. Also, previous studies have evaluated the role of HHVs in MS clinical course either with a cross-sectional study design or with a longitudinal design using serial measures within the same person,<sup><xref ref-type="bibr" rid="bibr8-1352458511428081">8</xref>,<xref ref-type="bibr" rid="bibr10-1352458511428081">10</xref>,<xref ref-type="bibr" rid="bibr12-1352458511428081">12</xref><xref ref-type="bibr" rid="bibr13-1352458511428081"/><xref ref-type="bibr" rid="bibr14-1352458511428081"/><xref ref-type="bibr" rid="bibr15-1352458511428081"/><xref ref-type="bibr" rid="bibr16-1352458511428081"/>–<xref ref-type="bibr" rid="bibr17-1352458511428081">17</xref></sup>, comparing anti-human herpesvirus measurements during exacerbation and remission. Here we prospectively evaluated the role of HHVs in relapses and progression in disability.</p>
<p>Our cohort was similar in terms of relapse occurrence<sup><xref ref-type="bibr" rid="bibr10-1352458511428081">10</xref>,<xref ref-type="bibr" rid="bibr12-1352458511428081">12</xref>,<xref ref-type="bibr" rid="bibr14-1352458511428081">14</xref></sup> and level of disability<sup><xref ref-type="bibr" rid="bibr12-1352458511428081">12</xref>,<xref ref-type="bibr" rid="bibr14-1352458511428081">14</xref>,<xref ref-type="bibr" rid="bibr17-1352458511428081">17</xref>,<xref ref-type="bibr" rid="bibr18-1352458511428081">18</xref>,<xref ref-type="bibr" rid="bibr20-1352458511428081">20</xref></sup> to other studies on this topic. Thus our results are likely generalizable to other European-descent populations at a minimum.</p>
<p>A limitation was that anti-HHV6 IgG and anti-EBV EBNA and VCA IgG were only measured at baseline, but these antibodies are relatively stable over time.<sup><xref ref-type="bibr" rid="bibr36-1352458511428081">36</xref>,<xref ref-type="bibr" rid="bibr37-1352458511428081">37</xref></sup> Our analysis found that the association persisted when we restricted the analysis period to 1 year and 6 months post anti-human herpesvirus IgG measurement, providing support that the observed finding reflects a true effect, rather than a statistical artifact.</p>
</sec>
</sec>
<sec id="section19-1352458511428081" sec-type="conclusions">
<title>Conclusion</title>
<p>To conclude, using one of the largest prospective cohorts and longest follow-up durations evaluating the role of anti-HHV-6 and anti-EBV IgG in MS clinical course, we found a significant, dose-dependent relationship between baseline-measured serum anti-HHV-6 IgG levels and the subsequent hazard of relapse. At the same time, while no association was found with disability or change in disability, the higher anti-HHV-6 IgG titers among progressive-course females relative to males indicate some interaction between anti-HHV-6 IgG and sex in the progressive MS course. Overall, these findings suggest that measuring anti-HHV-6 IgG levels in newly diagnosed RRMS cases may be an indicator of future disease activity and may allow stratification of high and low risk individuals after a first demyelinating event.</p>
</sec>
</body>
<back>
<ack>
<p>We would like to thank all the study participants and the research staff who assisted with this project, particularly our MSL research nurse P Groom.</p>
<p>The MSL study was designed and implemented by BT, IvM, FP, A-LP and TD. Anti-HHV-6 and anti-EBV IgG measurements were performed by DD and JT. Analyses were performed by SSJ under supervision by LB. Initial drafting of the manuscript was by SSJ, BT and IvM. All authors participated in critical revision of the manuscript and approve it for submission</p>
</ack>
<fn-group>
<fn fn-type="conflict">
<p>No authors have any financial conflicts to report.</p></fn>
<fn fn-type="financial-disclosure">
<p>The MS Longitudinal Study was funded by a grant from the Australian National Health &amp; Medical Research Council (Project 211308). Additional funding for 25(OH)D measures was provided by the Trish Foundation. The HHV-6 and EBV antibody levels were funded by a separate grant from NHMRC (Project 490020). IvM is supported by a fellowship from the Australian Research Council.</p></fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="bibr1-1352458511428081">
<label>1.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Santiago</surname><given-names>O</given-names></name>
<name><surname>Gutierrez</surname><given-names>J</given-names></name>
<name><surname>Sorlozano</surname><given-names>A</given-names></name>
<name><surname>de Dios Luna</surname><given-names>J</given-names></name>
<name><surname>Villegas</surname><given-names>E</given-names></name>
<name><surname>Fernandez</surname><given-names>O</given-names></name>
</person-group>. <article-title>Relation between Epstein-Barr virus and multiple sclerosis: analytic study of scientific production</article-title>. <source>Eur J Clin Microbiol Infect Dis</source> <year>2010</year>; <volume>29</volume>: <fpage>857</fpage>–<lpage>866</lpage>.</citation>
</ref>
<ref id="bibr2-1352458511428081">
<label>2.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Lucas</surname><given-names>RM</given-names></name>
<name><surname>Ponsonby</surname><given-names>AL</given-names></name>
<name><surname>Dear</surname><given-names>K</given-names></name>
<etal/>
</person-group>. <article-title>Current and past Epstein-Barr virus infection in risk of initial CNS demyelination</article-title>. <source>Neurology</source> <year>2011</year>; <volume>77</volume>: <fpage>371</fpage>–<lpage>379</lpage>.</citation>
</ref>
<ref id="bibr3-1352458511428081">
<label>3.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Moore</surname><given-names>FG</given-names></name>
<name><surname>Wolfson</surname><given-names>C</given-names></name>
</person-group>. <article-title>Human herpes virus 6 and multiple sclerosis</article-title>. <source>Acta Neurol Scand</source> <year>2002</year>; <volume>106</volume>: <fpage>63</fpage>–<lpage>83</lpage>.</citation>
</ref>
<ref id="bibr4-1352458511428081">
<label>4.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Christensen</surname><given-names>T</given-names></name>
</person-group>. <article-title>Human herpesviruses in MS</article-title>. <source>Int MS J</source> <year>2007</year>; <volume>14</volume>: <fpage>41</fpage>–<lpage>47</lpage>.</citation>
</ref>
<ref id="bibr5-1352458511428081">
<label>5.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Tejada-Simon</surname><given-names>MV</given-names></name>
<name><surname>Zang</surname><given-names>YC</given-names></name>
<name><surname>Hong</surname><given-names>J</given-names></name>
<name><surname>Rivera</surname><given-names>VM</given-names></name>
<name><surname>Zhang</surname><given-names>JZ</given-names></name>
</person-group>. <article-title>Cross-reactivity with myelin basic protein and human herpesvirus-6 in multiple sclerosis</article-title>. <source>Ann Neurol</source> <year>2003</year>; <volume>53</volume>: <fpage>189</fpage>–<lpage>197</lpage>.</citation>
</ref>
<ref id="bibr6-1352458511428081">
<label>6.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Lunemann</surname><given-names>JD</given-names></name>
<name><surname>Jelcic</surname><given-names>I</given-names></name>
<name><surname>Roberts</surname><given-names>S</given-names></name>
<etal/>
</person-group>. <article-title>EBNA1-specific T cells from patients with multiple sclerosis cross react with myelin antigens and co-produce IFN-{gamma} and IL-2</article-title>. <source>J Exp Med</source> <year>2008</year>; <volume>205</volume>: <fpage>1763</fpage>–<lpage>1773</lpage>.</citation>
</ref>
<ref id="bibr7-1352458511428081">
<label>7.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Cirone</surname><given-names>M</given-names></name>
<name><surname>Cuomo</surname><given-names>L</given-names></name>
<name><surname>Zompetta</surname><given-names>C</given-names></name>
<etal/>
</person-group>. <article-title>Human herpesvirus 6 and multiple sclerosis: a study of T cell cross-reactivity to viral and myelin basic protein antigens</article-title>. <source>J Med Virol</source> <year>2002</year>; <volume>68</volume>: <fpage>268</fpage>–<lpage>272</lpage>.</citation>
</ref>
<ref id="bibr8-1352458511428081">
<label>8.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Wandinger</surname><given-names>K</given-names></name>
<name><surname>Jabs</surname><given-names>W</given-names></name>
<name><surname>Siekhaus</surname><given-names>A</given-names></name>
<etal/>
</person-group>. <article-title>Association between clinical disease activity and Epstein-Barr virus reactivation in MS</article-title>. <source>Neurology</source> <year>2000</year>; <volume>55</volume>: <fpage>178</fpage>–<lpage>184</lpage>.</citation>
</ref> <ref id="bibr9-1352458511428081">
<label>9.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Buljevac</surname><given-names>D</given-names></name>
<name><surname>van Doornum</surname><given-names>GJ</given-names></name>
<name><surname>Flach</surname><given-names>HZ</given-names></name>
<etal/>
</person-group>. <article-title>Epstein-Barr virus and disease activity in multiple sclerosis</article-title>. <source>J Neurol Neurosurg Psychiatry</source> <year>2005</year>; <volume>76</volume>: <fpage>1377</fpage>–<lpage>1381</lpage>.</citation>
</ref>
<ref id="bibr10-1352458511428081">
<label>10.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Berti</surname><given-names>R</given-names></name>
<name><surname>Brennan</surname><given-names>MB</given-names></name>
<name><surname>Soldan</surname><given-names>SS</given-names></name>
<etal/>
</person-group>. <article-title>Increased detection of serum HHV-6 DNA sequences during multiple sclerosis (MS) exacerbations and correlation with parameters of MS disease progression</article-title>. <source>J Neurovirol</source> <year>2002</year>; <volume>8</volume>: <fpage>250</fpage>–<lpage>256</lpage>.</citation>
</ref>
<ref id="bibr11-1352458511428081">
<label>11.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Alvarez-Lafuente</surname><given-names>R</given-names></name>
<name><surname>De Las Heras</surname><given-names>V</given-names></name>
<name><surname>Bartolome</surname><given-names>M</given-names></name>
<name><surname>Picazo</surname><given-names>JJ</given-names></name>
<name><surname>Arroyo</surname><given-names>R</given-names></name>
</person-group>. <article-title>Beta-interferon treatment reduces human herpesvirus-6 viral load in multiple sclerosis relapses but not in remission</article-title>. <source>Eur Neurol</source> <year>2004</year>; <volume>52</volume>: <fpage>87</fpage>–<lpage>91</lpage>.</citation>
</ref>
<ref id="bibr12-1352458511428081">
<label>12.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Höllsberg</surname><given-names>P</given-names></name>
<name><surname>Kusk</surname><given-names>M</given-names></name>
<name><surname>Bech</surname><given-names>E</given-names></name>
<name><surname>Hansen</surname><given-names>HJ</given-names></name>
<name><surname>Jakobsen</surname><given-names>J</given-names></name>
<name><surname>Haahr</surname><given-names>S</given-names></name>
</person-group>. <article-title>Presence of Epstein-Barr virus and human herpesvirus 6B DNA in multiple sclerosis patients: associations with disease activity</article-title>. <source>Acta Neurol Scand</source> <year>2005</year>; <volume>112</volume>: <fpage>395</fpage>–<lpage>402</lpage>.</citation>
</ref>
<ref id="bibr13-1352458511428081">
<label>13.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Alvarez-Lafuente</surname><given-names>R</given-names></name>
<name><surname>De Las Heras</surname><given-names>V</given-names></name>
<name><surname>Bartolome</surname><given-names>M</given-names></name>
<name><surname>Garcia-Montojo</surname><given-names>M</given-names></name>
<name><surname>Arroyo</surname><given-names>R</given-names></name>
</person-group>. <article-title>Human herpesvirus 6 and multiple sclerosis: a one-year follow-up study</article-title>. <source>Brain Pathol</source> <year>2006</year>; <volume>16</volume>: <fpage>20</fpage>–<lpage>27</lpage>.</citation>
</ref>
<ref id="bibr14-1352458511428081">
<label>14.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Garcia-Montojo</surname><given-names>M</given-names></name>
<name><surname>De Las Heras</surname><given-names>V</given-names></name>
<name><surname>Dominguez-Mozo</surname><given-names>M</given-names></name>
<etal/>
</person-group>. <article-title>Human herpesvirus 6 and effectiveness of interferon beta 1b in multiple sclerosis patients</article-title>. <source>Eur J Neurol</source> <year>2011</year>; <volume>18</volume>: <fpage>1027</fpage>–<lpage>1035</lpage>.</citation>
</ref>
<ref id="bibr15-1352458511428081">
<label>15.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Goldberg</surname><given-names>SH</given-names></name>
<name><surname>Albright</surname><given-names>AV</given-names></name>
<name><surname>Lisak</surname><given-names>RP</given-names></name>
<name><surname>Gonzalez-Scarano</surname><given-names>F</given-names></name>
</person-group>. <article-title>Polymerase chain reaction analysis of human herpesvirus-6 sequences in the sera and cerebrospinal fluid of patients with multiple sclerosis</article-title>. <source>J Neurovirol</source> <year>1999</year>; <volume>5</volume>: <fpage>134</fpage>–<lpage>139</lpage>.</citation>
</ref>
<ref id="bibr16-1352458511428081">
<label>16.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Behzad-Behbahani</surname><given-names>A</given-names></name>
<name><surname>Mikaeili</surname><given-names>MH</given-names></name>
<name><surname>Entezam</surname><given-names>M</given-names></name>
<etal/>
</person-group>. <article-title>Human herpesvirus-6 viral load and antibody titer in serum samples of patients with multiple sclerosis</article-title>. <source>J Microbiol Immunol Infect</source> <year>2011</year>; <volume>44</volume>: <fpage>247</fpage>–<lpage>251</lpage>.</citation>
</ref>
<ref id="bibr17-1352458511428081">
<label>17.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Farrell</surname><given-names>RA</given-names></name>
<name><surname>Antony</surname><given-names>D</given-names></name>
<name><surname>Wall</surname><given-names>GR</given-names></name>
<etal/>
</person-group>. <article-title>Humoral immune response to EBV in multiple sclerosis is associated with disease activity on MRI</article-title>. <source>Neurology</source> <year>2009</year>; <volume>73</volume>: <fpage>32</fpage>–<lpage>38</lpage>.</citation>
</ref>
<ref id="bibr18-1352458511428081">
<label>18.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Castellazzi</surname><given-names>M</given-names></name>
<name><surname>Tamborino</surname><given-names>C</given-names></name>
<name><surname>Cani</surname><given-names>A</given-names></name>
<etal/>
</person-group>. <article-title>Epstein-Barr virus-specific antibody response in cerebrospinal fluid and serum of patients with multiple sclerosis</article-title>. <source>Mult Scler</source> <year>2010</year>; <volume>16</volume>: <fpage>883</fpage>–<lpage>887</lpage>.</citation>
</ref>
<ref id="bibr19-1352458511428081">
<label>19.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ingram</surname><given-names>G</given-names></name>
<name><surname>Bugert</surname><given-names>JJ</given-names></name>
<name><surname>Loveless</surname><given-names>S</given-names></name>
<name><surname>Robertson</surname><given-names>NP</given-names></name>
</person-group>. <article-title>Anti-EBNA-1 IgG is not a reliable marker of multiple sclerosis clinical disease activity</article-title>. <source>Eur J Neurol</source> <year>2010</year>; <volume>17</volume>: <fpage>1386</fpage>–<lpage>1389</lpage>.</citation>
</ref>
<ref id="bibr20-1352458511428081">
<label>20.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Villoslada</surname><given-names>P</given-names></name>
<name><surname>Juste</surname><given-names>C</given-names></name>
<name><surname>Tintore</surname><given-names>M</given-names></name>
<etal/>
</person-group>. <article-title>The immune response against herpesvirus is more prominent in the early stages of MS</article-title>. <source>Neurology</source> <year>2003</year>; <volume>60</volume>: <fpage>1944</fpage>–<lpage>1948</lpage>.</citation>
</ref>
<ref id="bibr21-1352458511428081">
<label>21.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Soldan</surname><given-names>SS</given-names></name>
<name><surname>Berti</surname><given-names>R</given-names></name>
<name><surname>Salem</surname><given-names>N</given-names></name>
<etal/>
</person-group>. <article-title>Association of human herpes virus 6 (HHV-6) with multiple sclerosis: increased IgM response to HHV-6 early antigen and detection of serum HHV-6 DNA</article-title>. <source>Nat Med</source> <year>1997</year>; <volume>3</volume>: <fpage>1394</fpage>–<lpage>1397</lpage>.</citation>
</ref>
<ref id="bibr22-1352458511428081">
<label>22.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Pittas</surname><given-names>F</given-names></name>
<name><surname>Ponsonby</surname><given-names>AL</given-names></name>
<name><surname>van der Mei</surname><given-names>IA</given-names></name>
<etal/>
</person-group>. <article-title>Smoking is associated with progressive disease course and increased progression in clinical disability in a prospective cohort of people with multiple sclerosis</article-title>. <source>J Neurol</source> <year>2009</year>; <volume>256</volume>: <fpage>577</fpage>–<lpage>585</lpage>.</citation>
</ref>
<ref id="bibr23-1352458511428081">
<label>23.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Simpson</surname><given-names>SL</given-names><suffix>Jr</suffix></name>
<name><surname>Taylor</surname><given-names>B</given-names></name>
<name><surname>Blizzard</surname><given-names>L</given-names></name>
<etal/>
</person-group>. <article-title>Higher 25-hydroxyvitamin D is associated with lower relapse risk in MS</article-title>. <source>Ann Neurol</source> <year>2010</year>; <volume>68</volume>: <fpage>193</fpage>–<lpage>203</lpage>.</citation>
</ref>
<ref id="bibr24-1352458511428081">
<label>24.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Tuke</surname><given-names>PW</given-names></name>
<name><surname>Hawke</surname><given-names>S</given-names></name>
<name><surname>Griffiths</surname><given-names>PD</given-names></name>
<name><surname>Clark</surname><given-names>DA</given-names></name>
</person-group>. <article-title>Distribution and quantification of human herpesvirus 6 in multiple sclerosis and control brains</article-title>. <source>Mult Scler</source> <year>2004</year>; <volume>10</volume>: <fpage>355</fpage>–<lpage>359</lpage>.</citation>
</ref>
<ref id="bibr25-1352458511428081">
<label>25.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Challoner</surname><given-names>PB</given-names></name>
<name><surname>Smith</surname><given-names>KT</given-names></name>
<name><surname>Parker</surname><given-names>JD</given-names></name>
<etal/>
</person-group>. <article-title>Plaque-associated expression of human herpesvirus 6 in multiple sclerosis</article-title>. <source>Proc Natl Acad Sci U S A</source> <year>1995</year>; <volume>92</volume>: <fpage>7440</fpage>–<lpage>7444</lpage>.</citation>
</ref>
<ref id="bibr26-1352458511428081">
<label>26.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ahlqvist</surname><given-names>J</given-names></name>
<name><surname>Fotheringham</surname><given-names>J</given-names></name>
<name><surname>Akhyani</surname><given-names>N</given-names></name>
<name><surname>Yao</surname><given-names>K</given-names></name>
<name><surname>Fogdell-Hahn</surname><given-names>A</given-names></name>
<name><surname>Jacobson</surname><given-names>S</given-names></name>
</person-group>. <article-title>Differential tropism of human herpesvirus 6 (HHV-6) variants and induction of latency by HHV-6A in oligodendrocytes</article-title>. <source>J Neurovirol</source> <year>2005</year>; <volume>11</volume>: <fpage>384</fpage>–<lpage>394</lpage>.</citation>
</ref>
<ref id="bibr27-1352458511428081">
<label>27.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Donati</surname><given-names>D</given-names></name>
<name><surname>Martinelli</surname><given-names>E</given-names></name>
<name><surname>Cassiani-Ingoni</surname><given-names>R</given-names></name>
<etal/>
</person-group>. <article-title>Variant-specific tropism of human herpesvirus 6 in human astrocytes</article-title>. <source>J Virol</source> <year>2005</year>; <volume>79</volume>: <fpage>9439</fpage>–<lpage>9448</lpage>.</citation>
</ref>
<ref id="bibr28-1352458511428081">
<label>28.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Fotheringham</surname><given-names>J</given-names></name>
<name><surname>Williams</surname><given-names>EL</given-names></name>
<name><surname>Akhyani</surname><given-names>N</given-names></name>
<name><surname>Jacobson</surname><given-names>S</given-names></name>
</person-group>. <article-title>Human herpesvirus 6 (HHV-6) induces dysregulation of glutamate uptake and transporter expression in astrocytes</article-title>. <source>J Neuroimmune Pharmacol</source> <year>2008</year>; <volume>3</volume>: <fpage>105</fpage>–<lpage>116</lpage>.</citation>
</ref>
<ref id="bibr29-1352458511428081">
<label>29.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Yao</surname><given-names>K</given-names></name>
<name><surname>Graham</surname><given-names>J</given-names></name>
<name><surname>Akahata</surname><given-names>Y</given-names></name>
<name><surname>Oh</surname><given-names>U</given-names></name>
<name><surname>Jacobson</surname><given-names>S</given-names></name>
</person-group>. <article-title>Mechanism of neuroinflammation: enhanced cytotoxicity and IL-17 production via CD46 binding</article-title>. <source>J Neuroimmune Pharmacol</source> <year>2010</year>; <volume>5</volume>: <fpage>469</fpage>–<lpage>478</lpage>.</citation>
</ref>
<ref id="bibr30-1352458511428081">
<label>30.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Luttichau</surname><given-names>HR</given-names></name>
<name><surname>Clark-Lewis</surname><given-names>I</given-names></name>
<name><surname>Jensen</surname><given-names>PO</given-names></name>
<name><surname>Moser</surname><given-names>C</given-names></name>
<name><surname>Gerstoft</surname><given-names>J</given-names></name>
<name><surname>Schwartz</surname><given-names>TW</given-names></name>
</person-group>. <article-title>A highly selective CCR2 chemokine agonist encoded by human herpesvirus 6</article-title>. <source>J Biol Chem</source> <year>2003</year>; <volume>278</volume>: <fpage>10928</fpage>–<lpage>10933</lpage>.</citation>
</ref>
<ref id="bibr31-1352458511428081">
<label>31.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Christensen</surname><given-names>T</given-names></name>
</person-group>. <article-title>Association of human endogenous retroviruses with multiple sclerosis and possible interactions with herpes viruses</article-title>. <source>Rev Med Virol</source> <year>2005</year>; <volume>15</volume>: <fpage>179</fpage>–<lpage>211</lpage>.</citation>
</ref>
<ref id="bibr32-1352458511428081">
<label>32.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Blond</surname><given-names>JL</given-names></name>
<name><surname>Beseme</surname><given-names>F</given-names></name>
<name><surname>Duret</surname><given-names>L</given-names></name>
<etal/>
</person-group>. <article-title>Molecular characterization and placental expression of HERV-W, a new human endogenous retrovirus family</article-title>. <source>J Virol</source> <year>1999</year>; <volume>73</volume>: <fpage>1175</fpage>–<lpage>1185</lpage>.</citation>
</ref>
<ref id="bibr33-1352458511428081">
<label>33.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Perron</surname><given-names>H</given-names></name>
<name><surname>Bernard</surname><given-names>C</given-names></name>
<name><surname>Bertrand</surname><given-names>JB</given-names></name>
<etal/>
</person-group>. <article-title>Endogenous retroviral genes, Herpesviruses and gender in Multiple Sclerosis</article-title>. <source>J Neurol Sci</source> <year>2009</year>; <volume>286</volume>: <fpage>65</fpage>–<lpage>72</lpage>.</citation>
</ref>
<ref id="bibr34-1352458511428081">
<label>34.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Perron</surname><given-names>H</given-names></name>
<name><surname>Lazarini</surname><given-names>F</given-names></name>
<name><surname>Ruprecht</surname><given-names>K</given-names></name>
<etal/>
</person-group>. <article-title>Human endogenous retrovirus (HERV)-W ENV and GAG proteins: physiological expression in human brain and pathophysiological modulation in multiple sclerosis lesions</article-title>. <source>J Neurovirol</source> <year>2005</year>; <volume>11</volume>: <fpage>23</fpage>–<lpage>33</lpage>.</citation>
</ref>
<ref id="bibr35-1352458511428081">
<label>35.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Derfuss</surname><given-names>T</given-names></name>
<name><surname>Hohlfeld</surname><given-names>R</given-names></name>
<name><surname>Meinl</surname><given-names>E</given-names></name>
</person-group>. <article-title>Intrathecal antibody (IgG) production against human herpesvirus type 6 occurs in about 20% of multiple sclerosis patients and might be linked to a polyspecific B-cell response</article-title>. <source>J Neurol</source> <year>2005</year>; <volume>252</volume>: <fpage>968</fpage>–<lpage>971</lpage>.</citation>
</ref>
<ref id="bibr36-1352458511428081">
<label>36.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Braun</surname><given-names>DK</given-names></name>
<name><surname>Dominguez</surname><given-names>G</given-names></name>
<name><surname>Pellett</surname><given-names>PE</given-names></name>
</person-group>. <article-title>Human herpesvirus 6</article-title>. <source>Clin Microbiol Rev</source> <year>1997</year>; <volume>10</volume>: <fpage>521</fpage>–<lpage>567</lpage>.</citation>
</ref>
<ref id="bibr37-1352458511428081">
<label>37.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Iuliano</surname><given-names>R</given-names></name>
<name><surname>Trovato</surname><given-names>R</given-names></name>
<name><surname>Lico</surname><given-names>S</given-names></name>
<etal/>
</person-group>. <article-title>Human herpesvirus-6 reactivation in a longitudinal study of two HIV-1 infected patients</article-title>. <source>J Med Virol</source> <year>1997</year>; <volume>51</volume>: <fpage>259</fpage>–<lpage>264</lpage>.</citation>
</ref>
</ref-list>
</back>
</article>